Country for PR: United States
Contributor: PR Newswire New York
Friday, August 11 2017 - 06:42
Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method
ANN ARBOR, Mich., Aug. 11, 2017 /PRNewswire-AsiaNet/ --

- Study published in Science magazine demonstrates how epigenetic markers can 
identify cell subtypes and regulatory elements that drive cellular diversity

Swift Biosciences, a leading provider of innovative library prep solutions for 
next-generation sequencing (NGS), today announced the launch of a new 
single-cell methylation sequencing method based on its Accel-NGS(R) 
Adaptase(TM) technology ( 
), an efficient and robust NGS-prep solution for whole-genome bisulfite 
sequencing at single-cell resolution. This new method enables the efficient 
analysis of different methylated regions across thousands of cells from 
heterogeneous tissues, while also addressing applications, such as cell 
classification, regulation of cellular mechanisms in normal tissue, epigenetic 
alterations in disease states and evolutionary conservation of epigenomic 

Methylation is a stable biomarker that can be used to identify cell types and 
the regulatory elements underlying cell function. When coupled with single-cell 
RNA expression studies, single-cell methylation can elucidate the regulatory 
elements, in turn controlling the unique expression profiles of individual 
cells and differences between cells. Additionally, recent clinical studies have 
uncovered methylation patterns in diseases—such as cancer—which identify tumor 
type, assess tumor burden in liquid biopsies, and correlate with disease 
progression, prognosis and drug response.

This method was recently described in the Science paper entitled "Single Cell 
Methylomes Identify Neuronal Subtypes and Regulatory Elements in Mammalian 
Cortex" ( ) by collaborators 
at the Salk Institute, University of California San Diego and Swift 
Biosciences. The workflow combines fluorescence-activated cell sorting-based 
isolation, bisulfite conversion and Swift's Accel-NGS Adaptase module with 
other commercially available components. The published results demonstrated a 
greater than two-fold increase in read-mapping rates as compared to other 
methods; thereby, significantly improving the data output per sequencing run 
while reducing the overall cost. 

"This is one of many scientific collaboration in which Swift technologies is 
pushing the boundaries of science," said Timothy Harkins, president and CEO of 
Swift Biosciences and co-author on the paper. "We are excited about new 
insights into basic cellular processes, and the profound, future impact it will 
have on precision medicine."

"Our proprietary Adaptase technology constructs high-complexity NGS libraries 
from low-input, single-stranded DNA," said Laurie Kurihara, PhD, senior 
director of research and development and co-author on the paper. "Our 
single-cell workflow has fewer steps than other methods and offers multiplexed, 
single-cell processing to provide greater productivity for high-throughput 

The Accel-NGS Adaptase Module is now commercially available. 

SOURCE  Swift Biosciences

CONTACT: Darby Wagner, Lambert, Edwards & Associates, +1-616-258-5779,